CPMV
Mosaic ImmunoEngineering, Inc.0.4000
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
2.90MP/E (TTM)
-Basic EPS (TTM)
-0.09Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Mosaic ImmunoEngineering narrowed its Q3 operating loss to $144K from $186K y/y, while YTD loss shrank to $468K from $729K, thanks to payroll cuts in R&D and G&A. Cash burn slowed sharply to $83K YTD from $220K, leaving $32K on hand amid $7.4M liabilities that dwarf assets. Convertible notes at $1.4M net carry 8% interest with auto-conversion triggers; $200K loan payable hangs at 5%. Other income ticked up to $14K YTD from Oncotelic services. EPS loss of $0.07 YTD reconciles to 7.24M diluted shares. Cash won't last twelve months. Binding term sheet with Oncotelic expired unclosed. Key directors resigned in August. Litigation risks loom from IP and contracts.
10-Q
Q2 FY2025 results
Mosaic ImmunoEngineering narrowed its Q2 operating loss to $149K from $274K a year ago, while six-month loss eased to $353K from $582K, thanks to slashed R&D and G&A expenses from reduced payroll. Cash burn slowed sharply to $61K YTD versus $207K prior year, leaving $54K in cash against $7.2M liabilities including $1.4M convertible notes at 8% and $200K loan payable at 5%. Net loss exceeded operating by $21K due to non-cash interest on convertible notes. Oncotelic binding term sheet expired June 30 without close. Cash won't last twelve months without funding. Key directors resigned post-quarter.
10-Q
Q1 FY2025 results
Mosaic ImmunoEngineering narrowed its Q1 FY2025 operating loss to $175K from $269K y/y, trimming R&D 77% to $16K and G&A 21% to $159K via reduced payroll commitments. Net loss eased to $181K from $288K, with the $7K gap mainly from non-cash interest on convertible notes; diluted EPS of $(0.03) aligns with 7.2M shares. Cash burned $29K in operations, ending at $86K versus $115K q/q, with $200K loan payable and $1.4M convertible notes outstanding. A pending Oncotelic term sheet eyes clinical assets for $15M stock, extended to June 2025. Cash won't last twelve months. Substantial dilution looms from any deal.
10-K
FY2024 results
Mosaic ImmunoEngineering posted FY2024 net loss of $922K on minimal revenue, with expenses slashed—R&D down 58% to $184K, G&A down 28% to $696K—reflecting scaled-back operations amid cash crunch. Q4 saw $42K other income from Oncotelic advisory services, plus $200K convertible note inflow, lifting year-end cash to $115K against $5.5M current liabilities; repaid $70K Oncotelic loan. Binding term sheet eyes $15M stock-for-tech deal by June 2025, risking dilution. Cash won't last. Going concern in peril.
8-K
Term sheet extended to June
Mosaic ImmunoEngineering extended its binding term sheet with Oncotelic Therapeutics to June 30, 2025, for acquiring rights to clinical-stage necroptosis cancer therapies, VDAs, and AI immunotherapy tech. Consideration remains $15.0 million in stock upfront, plus up to $15.0 million in milestone shares. Due diligence continues. No deal guaranteed.
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
CMMB
Chemomab Therapeutics Ltd.
2.06+0.00
ENVB
Enveric Biosciences, Inc.
5.24-0.12
FBLG
FibroBiologics, Inc.
0.24-0.02
IMA
ImageneBio, Inc.
6.25+0.08
IMVT
Immunovant, Inc.
26.61+0.61
MURA
Mural Oncology plc
2.04+2.04
NWBO
Northwest Biotherapeutics, Inc.
0.25+0.01
PTIX
Protagenic Therapeutics, Inc.
1.52-0.07